LOGIN  |  REGISTER
Chimerix
C4 Therapeutics

Sotera Health to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 12, 2023 | Last Trade: US$13.21 0.40 -2.94

CLEVELAND, May 12, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will participate in an open forum discussion at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 4:35 pm Eastern. Sotera Health management will also participate in one-on-one meetings with investors during the conference.

Investors and the general public are invited to listen to the live webcast of Mr. Petras’ discussion by accessing the link on the Sotera Health website under the Investor Relations section: https://investors.soterahealth.com/events-and-presentations. A replay will also be made available.

About Sotera Health:

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

INVESTOR RELATIONS CONTACTS:                                
Jason Peterson
Vice President & Treasurer
Sotera Health Company
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Sally J. Curley, IRC
IR Advisory Solutions
This email address is being protected from spambots. You need JavaScript enabled to view it.
   
MEDIA CONTACT:  
Kristin Gibbs
Chief Marketing Officer
Sotera Health Company
This email address is being protected from spambots. You need JavaScript enabled to view it.
  
   
Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB